Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Androgen Receptor Antagonists
  • Bone Neoplasms
  • Castration
  • Prostatic Neoplasms
  • Thiohydantoins

abstract

  • ARN-509 was safe and well tolerated, displayed dose-proportional pharmacokinetics, and demonstrated pharmacodynamic and antitumor activity across all dose levels tested. A maximum efficacious dose of 240 mg daily was selected for phase II exploration based on integration of preclinical and clinical data.

publication date

  • October 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3782148

PubMed ID

  • 24002508

Additional Document Info

start page

  • 3525

end page

  • 30

volume

  • 31

number

  • 28